

Cell, Volume 183

Supplemental Information

Compromised Humoral Functional Evolution

Tracks with SARS-CoV-2 Mortality

Tomer Zohar, Carolin Loos, Stephanie Fischinger, Caroline Atyeo, Chuangqi Wang, Matthew D. Slein, John Burke, Jingyou Yu, Jared Feldman, Blake Marie Hauser, Tim Caradonna, Aaron G. Schmidt, Yongfei Cai, Hendrik Streeck, Edward T. Ryan, Dan H. Barouch, Richelle C. Charles, Douglas A. Lauffenburger, and Galit Alter

| Characteristic | Moderate (n = 82) | Severe (n = 76) | Deceased (n = 35) |
|---|--------------------------|------------------------|--------------------------|
| Female sex - no. (%) | 29 (35.3) | 29 (38.2) | 8 (22.9) |
| Age range - no. (%) | | | |
| Younger than 50 | 26 (31.7) | 25 (32.9) | 3 (8.58) |
| 50-59 | 11 (13.4) | 21 (27.6) | 6 (17.1) |
| 60-69 | 16 (19.5) | 17 (22.4) | 6 (17.1) |
| 70-79 | 17 (20.1) | 7 (9.21) | 7 (0.2) |
| 80 and older | 12 (14.6) | 6 (7.90) | 13 (37.1) |
| Clinical outcome - no. (%) | | | |
| D/C home | 59 (72.0) | 21 (27.6) | 0 (0) |
| D/C rehab/longterm care facility | 21 (26.8) | 55 (72.3) | 0 (0) |
| Death | 1 (1.22) | 0 (0) | 35 (100) |
| Days from onset of symptoms to sample collection - median (IQR) | 7 (6.75) | 9 (8.25) | 6 (8) |
| Number of time points - median (IQR) | 1 (1) | 2 (1.25) | 2 (1.5) |
| Acute respiratory distress syndrome - no. (%) ^a | 2 (2.44) | 43 (70.5) | 20 (74..1) |
| Immunosuppressed - no. (%) | 6 (7.32) | 3 (3.95) | 5 (14.3) |
| Past pulmonary disease - no (%) ^b | 19 (23.5) | 17 (23.3) | 15 (46.9) |
| Body-mass-index - median (IQR) ^c | 27.8 (8) | 30.9 (6.55) | 28.5 (8.83) |
| Treatment - no. (%) | | | |
| Remdesivir | 4 (4.89) | 14 (18.4) | 2 (5.71) |
| Inhaled nitric oxide | 4 (4.89) | 14 (18.4) | 7 (20.0) |
| Hydroxychloroquine | 55 (67.1) | 68 (89.5) | 33 (94.3) |
| Tocilizumab | 0 (0) | 2 (2.63) | 0 (0) |
| Azithromycin | 44 (53.7) | 69 (90.8) | 28 (80.0) |
| Ceftriaxone | 36 (43.9) | 60 (78.9) | 30 (85.7) |
| Vancomycin | 9 (11.0) | 53 (70.0) | 27 (77.1) |
| Sarilumab | 2 (2.44) | 1 (1.32) | 3 (8.57) |
| Lopinavir/Ritonavir | 0 (0) | 3 (3.95) | 0 (0) |